Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.76 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618447 | 0.90 | MAOB (0.62) | MAOBMEN1KMT2AHSP90AA1KDM4E | |
| SCHEMBL1067965 | 0.88 | MAOA (0.64) | MAOBSLC16A3CA12CA1CA2 | |
| SCHEMBL22148003 | 0.86 | MAOB (1.00) | MAOBSLC16A3CA12CA1CA2 | |
| SCHEMBL3626320 | 0.85 | PTGS2 (0.58) | MAOBCA12CA2CA4CA7 | |
| SCHEMBL1391034 | 0.85 | SLC16A3 (0.65) | MAOBSLC16A3CA12CA1CA2 | |
| SCHEMBL5866737 | 0.84 | SLC16A3 (0.72) | MAOBSLC16A3CA12CA1CA2 | |
| SCHEMBL2082963 | 0.84 | SLC16A3 (0.59) | MAOBSLC16A3CA12CA1CA2 | |
| SCHEMBL13740830 | 0.84 | CA12 (0.57) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL18591925 | 0.84 | CA12 (0.57) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL177458 | 0.82 | HPGD (0.70) | MAOBSLC16A3CA12CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| CN-102459251-B | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase | JANSSEN PHARMACEUTICA NV | 2015-05-20 | — | — | CN | disclosed |
| EP-2430019-B1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090062348-A1 | Antifungal Agent Containing Pyridine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062348-A1 | Antifungal Agent Containing Pyridine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062348-A1 | Antifungal Agent Containing Pyridine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1864980-A1 | ANTIFUNGAL AGENT CONTAINING PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864980-A1 | ANTIFUNGAL AGENT CONTAINING PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1687289-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051938-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | MAOB 1305/4885SLC16A3 3318/4885CA12 2537/4885 |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | MAOB 2860/4885SLC16A3 4425/4885CA12 3495/4885 |
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | MAOB 4810/4885SLC16A3 1051/4885CA12 4498/4885 |
| US-20090062348-A1 | Antifungal Agent Containing Pyridine Derivative | ERG28, SQOR, CYP51A1 | MAOB 710/4885SLC16A3 3786/4885CA12 2282/4885 |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MAOB 2860/4885SLC16A3 4425/4885CA12 3495/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MAOB 2860/4885SLC16A3 4425/4885CA12 3495/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MAOB 2860/4885SLC16A3 4425/4885CA12 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.